Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 11, 2024

Longitudinal Profiling Identifies Co-Occurring BRCA1/2 Reversions and TP53BP1, RIF1, and PAXIP1 Mutations in PARP Inhibitor–Resistant Advanced Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer
Ann. Oncol 2024 Jan 18;[EPub Ahead of Print], E Harvey-Jones, M Raghunandan, L Robbez-Masson, L Magraner-Pardo, T Alaguthurai, A Yablonovitch, J Yen, H Xiao, R Brough, J Frankum, F Song, J Yeung, T Savy, A Gulati, J Alexander, H Kemp, C Starling, A Konde, R Marlow, M Cheang, P Proszek, M Hubank, M Cai, J Trendell, R Lu, R Liccardo, N Ravindran, A Llop-Guevara, O Rodriguez, J Balmana, N Lukashchuk, M Dorschner, L Drusbosky, I Roxanis, V Serra, S Haider, SJ Pettitt, CJ Lord, ANJ Tutt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading